Efficacy and Safety of 2 Doses of Tiotropium Respimat Compared to Placebo in Adolescents With Severe Persistent Asthma

NCT01277523

Last updated date
Study Location
205.456.01004 Boehringer Ingelheim Investigational Site
Stockton, California, , United States
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Asthma
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
12-17 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

1. All patients and their parent(s) (or legally accepted representative) must sign and date respectively an informed assent and an informed consent consistent with International Conference on Harmonisation - Harmonised Tripartite Guideline for Good Clinical Practice (ICH-GCP) guidelines and local legislation prior to the patient's participation in the trial. A separate informed consent/assent is required for pharmacogenomic sampling.

2. Male or female patients between 12 and 17 years of age (at date of informed consent/assent).

3. All patients must have at least a 3-month history of asthma at the time of enrolment into the trial.

4. All patients must have been on maintenance treatment with an inhaled corticosteroid either at stable high dose in combination with another controller medication, OR at stable medium dose in combination with two other controller medications, for at least 4 weeks before Visit 1.

5. All patients must be symptomatic at Visit 1 (screening) and prior to randomisation at Visit 2 as defined by an Asthma Control Questionnaire (ACQ) mean score of = 1.5.

6. All patients must have a pre-bronchodilator Forced Expiratory Volume in 1 second (FEV1) = 60% and = 90% of predicted normal at Visit 1.

7. Variation of absolute FEV1 values of Visit 1 (pre-bronchodilator, considered as 100%) as compared to Visit 2 (pre-dose) must be within ± 30%.

8. All patients must confirm the diagnosis of asthma by bronchodilator reversibility at Visit 1, resulting in an increase in FEV1 of = 12% and = 200 mL 15 to 30 minutes after 400 µg salbutamol (albuterol). If patients in the lower age range (e.g. 12 to 14 year old patients) exhibit a very small total lung volume, positive reversibility testing might be based solely on the relative (=12%) post-bronchodilator response.

9. All patients must be never-smokers or ex-smokers who stopped smoking at least one year prior to enrolment.

10. Patients must be able to use the Respimat® inhaler correctly.

11. Patients must be able to perform all trial related procedures including technically acceptable spirometric manoeuvres according to American Thoracic Society/ European Respiratory Society (ATS/ERS) standards and use of the electronic diary/peak flow meter (diary compliance of at least 80% is required).

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


1. Significant disease other than asthma.


2. Abnormal haematology or blood chemistry.


3. History of heart disease, and/or hospitalised for cardiac syncope or failure.


4. Any unstable or life-threatening or requiring intervention or cardiac arrhythmia.


5. Malignancy for which the patient has undergone resection, radiation therapy or
chemotherapy.


6. Active tuberculosis.


7. Alcohol or drug abuse.


8. Thoracotomy with pulmonary resection.


9. Pulmonary rehabilitation program.


10. Hypersensitivity to anticholinergic drugs, or any components of the study medication
delivery system.


11. Pregnant or nursing adolescent female patients.


12. Female patients of child-bearing potential not using a highly effective method of
birth control.


13. Investigational drug within four weeks or six half lives prior to Visit 1.


14. Long-acting anticholinergics within four weeks prior to Visit 1.


15. Systemic corticosteroids at a high dose or at a not stable low dose within four weeks
prior to Visit 1.


16. Leukotriene modifiers if not stabilised for at least four weeks prior to Visit 1.


17. Long-acting theophylline preparations if not stabilised for at least two weeks prior
to Visit 1.


18. Anti Immunoglobulin E (Anti-IgE) treatment if not stabilised for at least six months
prior to Visit 1.


19. Cromones if not stabilised within four weeks prior to Visit 1.


20. Oral beta-blocker medication within four weeks prior to Visit 1.


21. Systemic oral or i.v. or s.c. beta-adrenergics within four weeks prior to Visit 1.


22. Other non-approved and according to international guidelines not recommended
experimental drugs for routine asthma therapy within four weeks prior to Visit 1.


23. Any acute asthma exacerbation or respiratory tract infection in the four weeks prior
to Visit 1and/or in the four weeks prior to Visit 2. In case of an asthma
deterioration occurring in the four weeks prior to Visit 1 and/or in the four weeks
prior to Visit 2, the visit must be postponed.


24. Randomised in this trial or currently participating in another trial.


25. Narrow-angle glaucoma, or any other disease where anticholinergic treatment is
contraindicated.


26. Moderate to severe renal impairment.


27. Patients requiring 10 or more puffs of rescue medication per day on more than 2
consecutive days in the four weeks prior to Visit 1 and/or in the four weeks prior to
Visit 2. In case of an asthma deterioration occurring in the four weeks prior to Visit
1 and/or in the four weeks prior to Visit 2, the visit must be postponed.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

AsthmaEfficacy and Safety of 3 Doses of Tiotropium Compared to Placebo in Adolescents (12 to 17 Yrs) With Moderate Asthma
NCT01122680
  1. Denver, Colorado
  2. Columbia, Missouri
  3. Warrensburg, Missouri
  4. Boys Town, Nebraska
  5. Canton, Ohio
  6. Koblenz,
  7. Rosenheim,
  8. Wesel,
  9. Balvi,
  10. Daugavpils,
  11. Rezekne,
  12. Riga,
  13. Riga,
  14. Vilnius,
  15. Vilnius,
  16. Vilnius,
  17. Kamnik,
  18. Ljubljana,
  19. Maribor,
ALL GENDERS
12 Years+
years
MULTIPLE SITES
AsthmaRandomised, Double- Blind, Cross-over Efficacy and Safety Comparison of Three Different Doses of Tiotropium Administered Once Daily Versus Placebo in Patients With Moderate Persistent Asthma.
NCT01233284
  1. Hallein,
  2. Linz,
  3. Neumarkt am Wallersee,
  4. Schlüsslberg,
  5. Thalheim bei Wels,
  6. Berlin,
  7. Berlin,
  8. Frankfurt,
  9. Hamburg,
  10. Hannover,
  11. Mainz,
  12. Schwerin,
  13. Wiesbaden,
  14. Wiesloch,
  15. Ivano-Frankivsk,
  16. Kharkiv,
  17. Kharkiv,
  18. Kiev,
  19. Kiev,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
AsthmaEvaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study II)
NCT00776984
  1. Fountain Valley, California
  2. Fresno, California
  3. Stockton, California
  4. Waterbury, Connecticut
  5. Pensacola, Florida
  6. Chicago, Illinois
  7. Normal, Illinois
  8. Louisville, Kentucky
  9. New Orleans, Louisiana
  10. Omaha, Nebraska
  11. Ocean, New Jersey
  12. Albany, New York
  13. Great Neck, New York
  14. Rockville Centre, New York
  15. High Point, North Carolina
  16. Canton, Ohio
  17. Upland, Pennsylvania
  18. Richmond, Virginia
  19. Concord, New South Wales
  20. Mississauga, Ontario
  21. Ottawa, Ontario
  22. Montreal, Quebec
  23. Aalborg,
  24. Aarhus C,
  25. Berlin,
  26. Hamburg,
  27. Lübeck,
  28. Rüdersdorf,
  29. Weinheim,
  30. Bussolengo (vr),
  31. Milano,
  32. Pavia,
  33. Pietra Ligure (sv),
  34. Himeji, Hyogo,
  35. Hiroshima, Hiroshima,
  36. Itabashi-ku, Tokyo,
  37. Kagoshima, Kagoshima,
  38. Kishiwada, Osaka,
  39. Kitakyusyu, Fukuoka,
  40. Koga, Fukuoka,
  41. Kurashiki, Okayama,
  42. Kurume, Fukuoka,
  43. Morioka, Iwate,
  44. Osaka-sayama, Osaka,
  45. Sendai, Miyagi,
  46. Seto, Aichi,
  47. Urasoe, Okinawa,
  48. Urasoe, Okinawa,
  49. Wakayama, Wakayama,
  50. Groningen,
  51. Leeuwarden,
  52. Schiedam,
  53. Auckland NZ,
  54. Christchurch,
  55. Newtown Wellington NZ,
  56. Tauranga,
  57. St. Petersburg,
  58. St. Petersburg,
  59. St. Petersburg,
  60. Belgrade,
  61. Nis,
  62. Sremska Kamenica,
  63. Bellville,
  64. Cape Town,
  65. Cape Town,
  66. Cape Town,
  67. Ankara,
  68. Ankara,
  69. Izmit,
  70. Kharkov,
  71. Kiev,
  72. Vinnytsya,
  73. Chertsey,
  74. Exeter,
  75. Windsor,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
AsthmaA Randomised, Double- Blind, Placebo Controlled, Cross-over Efficacy and Safety Comparison of Tiotropium 5 µg Once Daily and Tiotropium 2.5 µg Twice Daily for Four Weeks in Patients With Moderate Persistent Asthma
NCT01152450
  1. Linz,
  2. Schlüsslberg,
  3. Thalheim bei Wels,
  4. Wels,
  5. Brno,
  6. Kyjov,
  7. Kohtla-Järve,
  8. Tallinn,
  9. Großhansdorf,
  10. Hannover,
  11. Mannheim,
  12. Schwerin,
  13. Daugavpils,
  14. Riga,
  15. Riga,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Efficacy and Safety of 2 Doses of Tiotropium Respimat Compared to Placebo in Adolescents With Severe Persistent Asthma
Official Title  ICMJE A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution Delivered Via Respimat® Inhaler (2.5 mcg and 5 mcg Once Daily) Over 12 Weeks as add-on Controller Therapy on Top of Usual Care in Adolescents (12 to 17 Years Old) With Severe Persistent Asthma
Brief Summary

The overall purpose of the trial is to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat® inhaler (2.5 mcg and 5 mcg once daily) over 12 weeks, compared to placebo, as add-on controller therapy on top of usual care in adolescents (12 to 17 years old) with severe persistent asthma.

The primary objective of the trial is to demonstrate superiority of tiotropium (5 mcg and possibly 2.5 mcg once daily in the evening) over placebo with regard to the primary pulmonary function endpoint after 12 weeks of treatment.

Secondary objectives are to evaluate efficacy of tiotropium with regard to other endpoints, and to evaluate the safety of tiotropium, compared to placebo, as add-on controller therapy on top of usual care in this patient population.

Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Condition  ICMJE Asthma
Intervention  ICMJE
  • Drug: tiotropium high dose
    2 actuations once daily
  • Drug: placebo
    2 actuations once daily
  • Drug: tiotropium low dose
    2 actuations once daily
Study Arms  ICMJE
  • Experimental: A
    Intervention: Drug: tiotropium low dose
  • Experimental: B
    Intervention: Drug: tiotropium high dose
  • Placebo Comparator: C
    Intervention: Drug: placebo
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: September 23, 2013)
392
Original Estimated Enrollment  ICMJE
 (submitted: January 13, 2011)
192
Actual Study Completion Date  ICMJE October 2013
Actual Primary Completion Date October 2013   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion criteria:

  1. All patients and their parent(s) (or legally accepted representative) must sign and date respectively an informed assent and an informed consent consistent with International Conference on Harmonisation - Harmonised Tripartite Guideline for Good Clinical Practice (ICH-GCP) guidelines and local legislation prior to the patient's participation in the trial. A separate informed consent/assent is required for pharmacogenomic sampling.
  2. Male or female patients between 12 and 17 years of age (at date of informed consent/assent).
  3. All patients must have at least a 3-month history of asthma at the time of enrolment into the trial.
  4. All patients must have been on maintenance treatment with an inhaled corticosteroid either at stable high dose in combination with another controller medication, OR at stable medium dose in combination with two other controller medications, for at least 4 weeks before Visit 1.
  5. All patients must be symptomatic at Visit 1 (screening) and prior to randomisation at Visit 2 as defined by an Asthma Control Questionnaire (ACQ) mean score of = 1.5.
  6. All patients must have a pre-bronchodilator Forced Expiratory Volume in 1 second (FEV1) = 60% and = 90% of predicted normal at Visit 1.
  7. Variation of absolute FEV1 values of Visit 1 (pre-bronchodilator, considered as 100%) as compared to Visit 2 (pre-dose) must be within ± 30%.
  8. All patients must confirm the diagnosis of asthma by bronchodilator reversibility at Visit 1, resulting in an increase in FEV1 of = 12% and = 200 mL 15 to 30 minutes after 400 µg salbutamol (albuterol). If patients in the lower age range (e.g. 12 to 14 year old patients) exhibit a very small total lung volume, positive reversibility testing might be based solely on the relative (=12%) post-bronchodilator response.
  9. All patients must be never-smokers or ex-smokers who stopped smoking at least one year prior to enrolment.
  10. Patients must be able to use the Respimat® inhaler correctly.
  11. Patients must be able to perform all trial related procedures including technically acceptable spirometric manoeuvres according to American Thoracic Society/ European Respiratory Society (ATS/ERS) standards and use of the electronic diary/peak flow meter (diary compliance of at least 80% is required).

Exclusion criteria:

  1. Significant disease other than asthma.
  2. Abnormal haematology or blood chemistry.
  3. History of heart disease, and/or hospitalised for cardiac syncope or failure.
  4. Any unstable or life-threatening or requiring intervention or cardiac arrhythmia.
  5. Malignancy for which the patient has undergone resection, radiation therapy or chemotherapy.
  6. Active tuberculosis.
  7. Alcohol or drug abuse.
  8. Thoracotomy with pulmonary resection.
  9. Pulmonary rehabilitation program.
  10. Hypersensitivity to anticholinergic drugs, or any components of the study medication delivery system.
  11. Pregnant or nursing adolescent female patients.
  12. Female patients of child-bearing potential not using a highly effective method of birth control.
  13. Investigational drug within four weeks or six half lives prior to Visit 1.
  14. Long-acting anticholinergics within four weeks prior to Visit 1.
  15. Systemic corticosteroids at a high dose or at a not stable low dose within four weeks prior to Visit 1.
  16. Leukotriene modifiers if not stabilised for at least four weeks prior to Visit 1.
  17. Long-acting theophylline preparations if not stabilised for at least two weeks prior to Visit 1.
  18. Anti Immunoglobulin E (Anti-IgE) treatment if not stabilised for at least six months prior to Visit 1.
  19. Cromones if not stabilised within four weeks prior to Visit 1.
  20. Oral beta-blocker medication within four weeks prior to Visit 1.
  21. Systemic oral or i.v. or s.c. beta-adrenergics within four weeks prior to Visit 1.
  22. Other non-approved and according to international guidelines not recommended experimental drugs for routine asthma therapy within four weeks prior to Visit 1.
  23. Any acute asthma exacerbation or respiratory tract infection in the four weeks prior to Visit 1and/or in the four weeks prior to Visit 2. In case of an asthma deterioration occurring in the four weeks prior to Visit 1 and/or in the four weeks prior to Visit 2, the visit must be postponed.
  24. Randomised in this trial or currently participating in another trial.
  25. Narrow-angle glaucoma, or any other disease where anticholinergic treatment is contraindicated.
  26. Moderate to severe renal impairment.
  27. Patients requiring 10 or more puffs of rescue medication per day on more than 2 consecutive days in the four weeks prior to Visit 1 and/or in the four weeks prior to Visit 2. In case of an asthma deterioration occurring in the four weeks prior to Visit 1 and/or in the four weeks prior to Visit 2, the visit must be postponed.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 12 Years to 17 Years   (Child)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Argentina,   Australia,   Bulgaria,   Germany,   Guatemala,   Hungary,   Israel,   Latvia,   Mexico,   Philippines,   Portugal,   South Africa,   Ukraine,   United States
Removed Location Countries Italy,   Norway
 
Administrative Information
NCT Number  ICMJE NCT01277523
Other Study ID Numbers  ICMJE 205.456
2010-021778-13 ( EudraCT Number: EudraCT )
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Boehringer Ingelheim
Study Sponsor  ICMJE Boehringer Ingelheim
Collaborators  ICMJE Pfizer
Investigators  ICMJE
Study Chair:Boehringer IngelheimBoehringer Ingelheim
PRS Account Boehringer Ingelheim
Verification Date October 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP